Cormorant Asset Management, LP Avidity Biosciences, Inc. Transaction History
Cormorant Asset Management, LP
- $1.27 Billion
- Q4 2024
A detailed history of Cormorant Asset Management, LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,050,000 shares of RNA stock, worth $33.2 Million. This represents 2.41% of its overall portfolio holdings.
Number of Shares
1,050,000
Previous 1,050,000
-0.0%
Holding current value
$33.2 Million
Previous $48.2 Million
36.69%
% of portfolio
2.41%
Previous 3.38%
Shares
12 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
100MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$349 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$298 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$272 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$251 Million3.76% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.5MShares$237 Million3.18% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.65B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...